Co by měl kardiolog vědět o diabetu mellitu 2. typu a léčbě perorálními antidiabetiky
| Title in English | What a cardiologist should know about type 2 diabetes mellitus and oral antidiabetic therapy? |
|---|---|
| Authors | |
| Year of publication | 2011 |
| Type | Article in Periodical |
| Magazine / Source | Remedia |
| MU Faculty or unit | |
| Citation | |
| Field | Endocrinology, diabetology, metabolism, nutrition |
| Keywords | diabetes mellitus; metformin; cardiovascular complications; type 2 diabetes management |
| Description | The prevalence of type 2 diabetes mellitus (DM)is currently increasing in all developed countries of the world including the Czech republic. At the same time, an upward trend is observed in the rates of chronic complications in general and in micro- and macriovascular complications as the major cause of death in diabetic patients in particular.To prevent these complications, DM needs to be diagnosed and treated as early as possible. The first line therapy is metmorfin that should be given to practically all pre-diabetic and type 2 diabetic patients. The only exception are the patients who develop gastrointestinal adverse events or experience impairment of renal function. Since diabetic patients are at increased cardiovascular risk, the well-documented cardiovascular benefits of metmorfin should always be underlined. |
| Related projects: |